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Triple-negative breast cancer refers to an aggressive subtype of breast cancer in which the
tumor cells lack receptors for estrogen, progesterone and the HER2 protein on their surfaces.
This type of breast cancer does not respond to treatments such as hormone therapy, like tamox-
ifen and aromatase inhibitors, or drugs that target HER2, like Herceptin. It is important, there-
fore, the identification of new selective drugs for the treatment of these tumors.
Parthenolide (PN), a sesquiterpene lactone extracted from the medical plant Tanacetum parthe-
nium, exerts anticancer activity on several tumor cell lines in culture, acting through diverse
molecular mechanisms. Our previous studies have shown that the PN exerts strong cytotoxic
effects on MG63 osteosarcoma and SK-Mel28 melanoma cells, through a caspase-independ-
ent mechanism which is associated with production of oxidative stress. 
Recently, we have undertaken a study in order to investigate the antineoplastic activity of PN on
MDA-MB231 cells, a triple-negative breast cancer cell line. Our results demonstrated that this
compound reduced the viability of MDA-MB231 cells in a dose- and time- dependent manner.
This effect was not prevented by the addition of z-VAD-fmk, a general inhibitor of caspase, thus
suggesting a caspase-independent cell death. Time-course experiments provided evidence that
the cytotoxic effect of PN occurs in two different phases. In the first phase of treatment (8h) cells
resulted positive to monodansylcadaverine (MDC), a fluorochrome that binds to autophagic vac-
uoles. Prolonging the treatment (16h) MDC-positive cells lowered, and an increase of PI-posi-
tive population was found, suggesting the appearance of necrotic events. The study of the mode
of PN action provided evidence that treatment with parthenolide induces ROS generation, acti-
vation of JNK and inhibition of NF-kB activity. All these effects were prevented by the addition
of NAC, thus suggesting the involvement of oxidative stress.
The antineoplastic activity of PN has been also assayed in vivo employing diamminopartheno-
lide (DMAPT), a soluble analogue of PN. Nude mice bearing breast carcinoma MDA-MB231
xenografts were treated daily with DMAPT (50 mg/Kg). It was observed that DMAPT increased
survival of MDA-MB231 xenograft-bearing nude mice as well as reduced MDA-MB231
xenografts tumor growth. Moreover, immunohistochemical studies showed that DMAPT was
able to decrease the expression of MMP-2, MMP-9 and VEGF, all factors involved in metastat-
ic events.
These data suggest a possible use of parthenolide for the treatment of triple negative breast
cancers.
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